Future of Cardiovascular Pharmacology

Alessio Squassina, Mirko Manchia, Christina Mitropoulou, George P. Patrinos, Pharmacogenomics and Personalized Medicine: Bridging Genetic Knowledge and Clinical Practice Springer. pp. 1- 16 ,(2014) , 10.1007/978-3-642-37393-0_226-1

John C. Avise, The hope, hype, & reality of genetic engineering : remarkable stories from agriculture, industry, medicine, and the environment ,(2004)

David, C. Sane, Roles of transglutaminases in cardiac and vascular diseases Frontiers in Bioscience. ,vol. 12, pp. 2530- 2545 ,(2007) , 10.2741/2253

Rianne van Schie, Talitha Verhoef, Anke-Hilse Maitland-Van Der Zee, Anton de Boer, Felix van der Meer, Ken Redekop, Rahber Thariani, Future of Pharmacogenetics in Cardiovascular Diseases In: Gallelli, L, (ed.) Pharmacology. (2012). ,(2012) , 10.5772/27500

Markus Krane, Marcus-André Deutsch, Rüdiger Lange, Stefanie A. Doppler, Cardiac regeneration: current therapies—future concepts Journal of Thoracic Disease. ,vol. 5, pp. 683- 697 ,(2013) , 10.3978/J.ISSN.2072-1439.2013.08.71

Joseph A. Dimasi, Henry G. Grabowski, John Vernon, R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry International Journal of The Economics of Business. ,vol. 2, pp. 201- 219 ,(1995) , 10.1080/758519309

Steve Morgan, Paul Grootendorst, Joel Lexchin, Colleen Cunningham, Devon Greyson, The cost of drug development: A systematic review Health Policy. ,vol. 100, pp. 4- 17 ,(2011) , 10.1016/J.HEALTHPOL.2010.12.002

Elisabeth Pain, Designing a Career in Biomedical Engineering Science. ,(2010) , 10.1126/SCIENCE.CAREDIT.A1000059

Charles Kennedy, The importance of drug discovery for treatment of cardiovascular diseases Future Medicinal Chemistry. ,vol. 5, pp. 355- 357 ,(2013) , 10.4155/FMC.13.20

Joseph A. DiMasi, Henry G. Grabowski, The cost of biopharmaceutical R&D: is biotech different? Managerial and Decision Economics. ,vol. 28, pp. 469- 479 ,(2007) , 10.1002/MDE.1360